Erin R. Gardner - Concepedia

Author

Erin R. Gardner

Also Known As

E GARDNER, E Gardner, E. Gardner, E. R. Gardner, EDWARD GARDNER, Erin Gardner, Erin R Gardner, Erin R. Gardner, Erma Gardner, Estelle N Gardner

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

National Cancer Institute Science Applications International Corporation (United States)Center for Cancer Research National Institutes of Health St. Jude Children's Research Hospital

About

Erin R. Gardner is an author at National Cancer Institute specializing in medicine, pharmacology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	1.5K
2	Health Sciences	2	2	740
3	Natural Sciences	1	1	80
4	Public Health	1	1	43
5	Biochemistry	1	1	17

Erin R. Gardner

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma Richard Piekarz, Robin Frye, Maria L. Turner, Journal of Clinical Oncology ImmunologyPathologyPharmacotherapyMetronomic ChemotherapyDermatology	2009	728
Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis <i>In vitro</i> and <i>In vivo</i> Joell J. Gills, Jaclyn LoPiccolo, Junji Tsurutani, Clinical Cancer Research	2007	326
Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation Christina Therapontos, Lynda Erskine, Erin R. Gardner, Proceedings of the National Academy of Sciences Limb DefectsDevelopmental BiologyAngiogenesisXenotransplantationLimb Morphogenesis	2009	253
Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and<i>nab</i>-Paclitaxel Erin R. Gardner, William L. Dahut, Charity D. Scripture, Clinical Cancer Research	2008	216
A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer Ronan J. Kelly, Deborah Draper, Clara C. Chen, Clinical Cancer Research	2010	172
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib Erin R. Gardner, Henry Burger, R VANSCHAIK, Clinical Pharmacology & Therapeutics	2006	142
Population pharmacokinetic analysis of sorafenib in patients with solid tumours Lokesh Jain, Sukyung Woo, Erin R. Gardner, British Journal of Clinical Pharmacology	2011	142
Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies Shivaani Kummar, Martin Gutierrez, Erin R. Gardner, Clinical Cancer Research	2007	130
Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia Cody J. Peer, Tristan M. Sissung, AeRang Kim, Clinical Cancer Research	2012	129
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies Shivaani Kummar, Martin Gutierrez, Erin R. Gardner, European Journal of Cancer OncologyMedicinePharmacotherapyAnti-cancer AgentAdvanced Malignancies	2009	122

Page 1